US2015209373A1PendingUtilityA1

Progesterone Receptor Modulators for Use in Preventing or Treating Androgen Mediated Diseases

40
Assignee: PREGLEM SAPriority: May 16, 2012Filed: May 15, 2013Published: Jul 30, 2015
Est. expiryMay 16, 2032(~5.8 yrs left)· nominal 20-yr term from priority
Inventors:Oliver PohlJean-Pierre Gotteland
A61P 5/26A61P 43/00A61P 5/24A61P 5/28A61P 35/00A61P 13/08A61P 17/06A61P 17/00A61P 17/08A61P 15/12A61P 17/02A61P 17/10A61P 17/14A61P 15/00A61K 31/00A61K 31/57
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates generally to a progesterone receptor modulator, or any metabolite thereof for use in the prevention or treatment of androgen mediated diseases characterized in that said progesterone receptor modulator, or any metabolite thereof, is administered to a subject in need thereof.

Claims

exact text as granted — not AI-modified
1 - 6 . (canceled) 
     
     
         7 . A kit comprising an effective amount of a progesterone receptor modulator, a Selective Progesterone Receptor Modulator (SPRM), or a metabolite thereof, that is effective for the treatment of an androgen mediated disease selected from the group consisting of Benign prostate hypertrophy (BPH), premenstrual syndrome (PMS), polycystic ovary syndrome (PCOS), prostate cancer, hirsutism, acne, seborrhea and androgenic alopecia, and optionally instructions for use. 
     
     
         8 . A method for preventing or treating an androgen mediated disease comprising administering a therapeutically effective amount of a progesterone receptor modulator, or a metabolite thereof to a subject in need thereof, wherein the androgen mediated disease is BPH or prostate cancer. 
     
     
         9 . The method according to  claim 8 , wherein the progesterone receptor modulator is a selective progesterone receptor modulator (SPRM), or a metabolite thereof. 
     
     
         10 . (canceled) 
     
     
         11 . The method according to  claim 9 , wherein the selective progesterone receptor modulator is CDB-2914 (ulipristal acetate), or a metabolite thereof. 
     
     
         12 . The method according to  claim 11 , wherein the CDB-2914 (ulipristal acetate) or the metabolite thereof is administered in a dose of 1 to 500 mg. 
     
     
         13 . The method according to  claim 12 , wherein the subject is a human. 
     
     
         14 . The kit according to  claim 7 , wherein the kit comprises a SPRM or a metabolite thereof that is effective for the treatment of BPH or prostate cancer. 
     
     
         15 . The kit according to  claim 14 , wherein the SPRM is CDB-2914 and the metabolite is selected from the group consisting of monodemethylated CDB-2914 (CDB-3877), didemethylated CDB-2914 (CDB-3963), 17alpha-hydroxy CDB-2914 (CDB-3236), and CDB-4183. 
     
     
         16 . The kit according to  claim 7 , wherein the kit comprises a SPRM or a metabolite thereof that is effective for the treatment of PMS, PCOS, hirsutism, acne, seborrhea, or androgenic alopecia. 
     
     
         17 . The kit according to  claim 16 , wherein the SPRM is CDB-2914 and the metabolite is selected from the group consisting of monodemethylated CDB-2914 (CDB-3877), didemethylated CDB-2914 (CDB-3963), 17alpha-hydroxy CDB-2914 (CDB-3236), and CDB-4183. 
     
     
         18 . The method according to  claim 12 , wherein the androgen mediated disease is BPH. 
     
     
         19 . The method of  claim 12  wherein the androgen mediated disease is prostate cancer. 
     
     
         20 . The method of  claim 12  wherein the CDB-2914 or the metabolite thereof is administered orally. 
     
     
         21 . The method according to  claim 12 , wherein the metabolite is selected from the group consisting of monodemethylated CDB-2914 (CDB-3877), didemethylated CDB-2914 (CDB-3963), 17alpha-hydroxy CDB-2914 (CDB-3236), and CDB-4183. 
     
     
         22 . A method for treating an androgen mediated disease in a female in need thereof comprising administering to the female a dose of between 1 to 500 mg CDB-2914 or a metabolite thereof, wherein the androgen mediated disease is PMS, PCOS, hirsutism, acne, seborrhea, or androgenic alopecia. 
     
     
         23 . The method according to  claim 22 , wherein the metabolite is selected from the group consisting of monodemethylated CDB-2914 (CDB-3877), didemethylated CDB-2914 (CDB-3963), 17alpha-hydroxy CDB-2914 (CDB-3236), and CDB-4183. 
     
     
         24 . The method according to  claim 22 , wherein the androgen mediated disease is PMS. 
     
     
         25 . The method according to  claim 22 , wherein the CDB-2914 or the metabolite thereof is administered orally. 
     
     
         26 . The method according to  claim 22 , wherein the CDB-2914 or the metabolite thereof is administered vaginally. 
     
     
         27 . The method according to  claim 22 , wherein the androgen mediated disease is PCOS.

Join the waitlist — get patent alerts

Track US2015209373A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.